<DOC>
	<DOCNO>NCT01350973</DOCNO>
	<brief_summary>The purpose study determine efficacy safety TAK-085 , daily ( QD ) twice daily ( BID ) , compare ethyl eicosapentaenoate ( EPA-E ) , three time daily ( TID ) participant hypertriglyceridemia undergoing lifestyle modification .</brief_summary>
	<brief_title>Efficacy TAK-085 Participants With Hypertriglyceridemia</brief_title>
	<detailed_description>TAK-085 oral capsule medicine license Takeda Pharmaceutical Company Ltd. TAK-085 contain omega-3 fatty acid ethyl ( mainly , ethyl eicosapentaenoate ( EPA-E ) ethyl docosahexaenoic acid ( DHA-E ) ) . This phase 3 , double-blind , randomize study evaluate efficacy safety TAK-085 compare EPA-E participant hypertriglyceridemia undergo lifestyle modification . The study period total 20 week , comprise 8- week screen period 12 week treatment .</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Eicosapentaenoic acid ethyl ester</mesh_term>
	<criteria>1 . Participants value fast triglyceride level Visit 2 ( Week 4 ) Visit 3 ( Week 2 ) 150 mg/dL high less 750 mg/dL , difference 2 value within 30 % high one . 2 . Participants differences 2 value fast Low density lipoprotein cholesterol level measure Visit 2 ( Week 4 ) Visit 3 ( Week 2 ) within 25 % high one . 1 . Participants coronary artery disease ( eg , confirm myocardial infarction angina pectoris ) within 6 month prior Visit 1 ( Week 8 ) participant history revascularization . 2 . Participants receive aortic aneurysmectomy complicate aortic aneurysm within 6 month prior Visit 1 ( Week 8 ) . 3 . Participants history complication clinically significant hemorrhagic disease ( eg , hemophilia , capillary fragility illness , digestive tract ulcer , urinary tract hemorrhage , hemoptysis , vitreous haemorrhage forth ) within 6 month prior Visit 1 ( Week 8 ) . 4 . Participants diagnose pancreatitis . 5 . Participants diagnose lipoprotein lipase ( LPL ) deficiency , apolipoprotein CII deficiency type III familial hyperlipidemia . 6 . Participants complication Cushing 's syndrome , uremia , systemic lupus erythematosus ( SLE ) serum dysproteinemia .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>